Aigen Investment Management LP Has $732,000 Position in The Cooper Companies, Inc. (NASDAQ:COO)

Aigen Investment Management LP lowered its position in The Cooper Companies, Inc. (NASDAQ:COO) by 16.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,632 shares of the medical device company’s stock after selling 1,351 shares during the quarter. Aigen Investment Management LP’s holdings in Cooper Companies were worth $732,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Innealta Capital LLC acquired a new stake in shares of Cooper Companies during the 2nd quarter worth about $25,000. Ashton Thomas Securities LLC acquired a new stake in shares of Cooper Companies during the 3rd quarter worth about $25,000. Covestor Ltd lifted its stake in shares of Cooper Companies by 305.9% during the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after buying an additional 208 shares during the last quarter. Crewe Advisors LLC lifted its stake in shares of Cooper Companies by 286.4% during the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after buying an additional 252 shares during the last quarter. Finally, Tortoise Investment Management LLC lifted its stake in shares of Cooper Companies by 75.4% during the 2nd quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock worth $34,000 after buying an additional 169 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Price Performance

COO stock opened at $101.88 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The Cooper Companies, Inc. has a 12 month low of $82.21 and a 12 month high of $112.38. The firm has a market cap of $20.29 billion, a P/E ratio of 56.76, a P/E/G ratio of 2.20 and a beta of 0.99. The company’s 50-day moving average price is $107.10 and its two-hundred day moving average price is $97.85.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. During the same period last year, the firm earned $0.84 EPS. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, analysts anticipate that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Cooper Companies

In related news, CEO Albert G. White III sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the sale, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Albert G. White III sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the sale, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brian G. Andrews sold 24,788 shares of Cooper Companies stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the sale, the chief financial officer now owns 6,614 shares in the company, valued at approximately $700,422.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 256,373 shares of company stock valued at $27,637,427 in the last ninety days. 2.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on COO. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Stifel Nicolaus restated a “buy” rating and set a $115.00 target price (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Wells Fargo & Company lifted their price objective on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Morgan Stanley lifted their price objective on shares of Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 10th. Finally, StockNews.com upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Cooper Companies presently has an average rating of “Moderate Buy” and an average price target of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.